Login to Your Account



Medicines' Oritavancin Strong In Confirmatory Phase III Trial

By Randy Osborne
Staff Writer

Wednesday, July 3, 2013
Another set of positive Phase III data with oritavancin, a semi-synthetic lipoglycopeptide antibiotic, in acute bacterial skin and skin structure infections (ABSSSIs) puts The Medicines Co. in line for a 2014 approval, and possibly a partnership to help commercialize the compound, which treats disorders caused by susceptible gram-positive bugs that include methicillin-resistant Staphylococcus aureus (MRSA).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription